Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol

INTRODUCTION: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. tEPs with pretreatment serum human chorionic gonadotrophin (hCG) levels <1000 IU/L respond well to outpatient medical treatment with intramuscular methotrexate (MTX). TEPs with hCG >1000 I...

Descripción completa

Detalles Bibliográficos
Autores principales: Horne, Andrew W, Skubisz, Monika M, Doust, Ann, Duncan, W Colin, Wallace, Euan, Critchley, Hilary O D, Johns, Terrance G, Norman, Jane E, Bhattacharya, Siladitya, Mollison, Jill, Rassmusen, Michael, Tong, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Obstetrics and Gynaecology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717468/
https://www.ncbi.nlm.nih.gov/pubmed/23872290
http://dx.doi.org/10.1136/bmjopen-2013-002902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717468/
https://www.ncbi.nlm.nih.gov/pubmed/23872290
http://dx.doi.org/10.1136/bmjopen-2013-002902

Ejemplares similares